Can we identify who gets benefit or harm from mycophenolate mofetil in systemic lupus erythematosus? A systematic review

被引:6
作者
Mendoza-Pinto, Claudia [1 ]
Pirone, Carmelo [2 ]
van der Windt, Danielle A. [3 ]
Parker, Ben [4 ,5 ]
Bruce, Ian N. [4 ,6 ]
机构
[1] Mexican Inst Social Secur, Reg Gen Hosp CIBIOR 36, Syst Autoimmune Dis Res Unit, Puebla, Mexico
[2] Sapienza Univ Rome, Dept Internal Med, Med Specialties Rheumatol Unit, Rome, Italy
[3] Keele Univ, Arthrit Res UK Primary Care Ctr, Res Inst Primary Care & Hlth Sci, Keele, Staffs, England
[4] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, NIHR Manchester Musculoskeletal Biomed Res Unit, Oxford Rd, Manchester, Lancs, England
[5] Univ Manchester, Manchester Acad Hlth Sci Ctr, Ctr Musculoskeletal Res, Fac Biol Med & Hlth, Manchester, Lancs, England
[6] Univ Manchester, Manchester Acad Hlth Sci Ctr, Arthrit Res UK Ctr Epidemiol, Fac Biol Med & Hlth, Oxford Rd, Manchester, Lancs, England
基金
英国惠康基金; 英国医学研究理事会;
关键词
Systemic lupus erythematosus; Mycophenolate mofetil; Systematic review; Prognosis; INTRAVENOUS CYCLOPHOSPHAMIDE; MAINTENANCE THERAPY; NEPHRITIS TREATMENT; INDUCTION TREATMENT; POLYMORPHISMS; DISEASE; ACID; PHARMACOKINETICS; AZATHIOPRINE; ASSOCIATION;
D O I
10.1016/j.semarthrit.2017.01.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: We aimed to summarize the evidence examining factors that predict differential response to mycophenolate mofetil (MMF) in systemic lupus erythematosus (SLE). Methods: Systematic searches of randomized clinical trials (RCT) to identify predictors of the effects of MMF (moderators), and cohort studies to explore prognostic factors associated with MMF outcomes (response, relapse, or adverse events) were performed. Two reviewers independently assessed the methodological quality of RCTs using the Cochrane Collaboration risk of bias tool and cohort studies using the QUality In Prognosis Studies tool. The quality of subgroup analysis, providing evidence for moderation, was evaluated. The Grading of Recommendations Assessment, Development, and Evaluation working group approach summarized the quality of evidence (QoE), considering the risk of bias, imprecision, inconsistency, indirectness, and publication bias. Results: From 26 studies (13 from 7 RCTs and 13 cohort studies) we found low QoE evidence for Black/Hispanic race/ethnicity predicting better renal responses to MMF in lupus nephritis (LN) from one RCT. There was low QoE evidence from cohort studies that a higher baseline creatinine and membranous features on renal biopsy were associated with poorer responses in LN. There was very low QoE for other moderators or prognostic factors associated with MMF treatment outcomes. QoE from RCTs was affected by exploratory or insufficient evidence from subgroup analysis and in both study types high risk of bias, indirectness and imprecision also affected QoE. Conclusions: In SLE, evidence for predictors of response to MMF is limited and none can be recommended for use in routine clinical practice. Specific studies of predictors measured at baseline and during treatment are needed with a priori hypotheses based on preliminary evidence to date and with sufficient power to determine which factors can be employed in clinical decision making. (C) 2017 The Authors. Published by Elsevier HS Journals, Inc.
引用
收藏
页码:65 / 78
页数:14
相关论文
共 56 条
[1]   Pharmacokinetics of Concentration-Controlled Mycophenolate Mofetil in Proliferative Lupus Nephritis: An Observational Cohort Study [J].
Alexander, Suceena ;
Fleming, Denise H. ;
Mathew, Binu S. ;
Varughese, Santosh ;
Jeyaseelan, Visalakshi ;
Tamilarasi, Veerasamy ;
Jacob, Chakko K. ;
John, George T. .
THERAPEUTIC DRUG MONITORING, 2014, 36 (04) :423-432
[2]  
[Anonymous], COCHRANE HDB SYSTEMA
[3]   Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis [J].
Appel, Gerald B. ;
Contreras, Gabriel ;
Dooley, Mary Anne ;
Ginzler, Ellen M. ;
Isenberg, David ;
Jayne, David ;
Li, Lei-Shi ;
Mysler, Eduardo ;
Sanchez-Guerrero, Jorge ;
Solomons, Neil ;
Wofsy, David .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (05) :1103-1112
[4]   GRADE guidelines: 3. Rating the quality of evidence [J].
Balshem, Howard ;
Helfand, Mark ;
Schuenemann, Holger J. ;
Oxman, Andrew D. ;
Kunz, Regina ;
Brozek, Jan ;
Vist, Gunn E. ;
Falck-Ytter, Yngve ;
Meerpohl, Joerg ;
Norris, Susan ;
Guyatt, Gordon H. .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2011, 64 (04) :401-406
[5]   EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs [J].
Bertsias, G. K. ;
Ioannidis, J. P. A. ;
Aringer, M. ;
Bollen, E. ;
Bombardieri, S. ;
Bruce, I. N. ;
Cervera, R. ;
Dalakas, M. ;
Doria, A. ;
Hanly, J. G. ;
Huizinga, T. W. J. ;
Isenberg, D. ;
Kallenberg, C. ;
Piette, J. C. ;
Schneider, M. ;
Scolding, N. ;
Smolen, J. ;
Stara, A. ;
Tassiulas, I. ;
Tektonidou, M. ;
Tincani, A. ;
van Buchem, M. A. ;
van Vollenhoven, R. ;
Ward, M. ;
Gordon, C. ;
Boumpas, D. T. .
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (12) :2074-2082
[6]   Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis [J].
Bertsias, George K. ;
Tektonidou, Maria ;
Amoura, Zahir ;
Aringer, Martin ;
Bajema, Ingeborg ;
Berden, Jo H. M. ;
Boletis, John ;
Cervera, Ricard ;
Doerner, Thomas ;
Doria, Andrea ;
Ferrario, Franco ;
Floege, Juergen ;
Houssiau, Frederic A. ;
Ioannidis, John P. A. ;
Isenberg, David A. ;
Kallenberg, Cees G. M. ;
Lightstone, Liz ;
Marks, Stephen D. ;
Martini, Alberto ;
Moroni, Gabriela ;
Neumann, Irmgard ;
Praga, Manuel ;
Schneider, Matthias ;
Starra, Argyre ;
Tesar, Vladimir ;
Vasconcelos, Carlos ;
van Vollenhoven, Ronald F. ;
Zakharova, Helena ;
Haubitz, Marion ;
Gordon, Caroline ;
Jayne, David ;
Boumpas, Dimitrios T. .
ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (11) :1771-1782
[7]   Long-term outcomes-mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases [J].
Cortes-Hernandez, Josefina ;
Teresa Torres-Salido, Maria ;
Segarra Medrano, Alfonso ;
Vilardell Tarres, Miquel ;
Ordi-Ros, Josep .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (12) :3939-3948
[8]   Identification of Biomarkers That Predict Response to Treatment of Lupus Nephritis With Mycophenolate Mofetil or Pulse Cyclophosphamide [J].
Dall'Era, Maria ;
Stone, David ;
Levesque, Victoria ;
Cisternas, Miriam ;
Wofsy, David .
ARTHRITIS CARE & RESEARCH, 2011, 63 (03) :351-357
[9]   Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis [J].
Dooley, Mary Anne ;
Jayne, David ;
Ginzler, Ellen M. ;
Isenberg, David ;
Olsen, Nancy J. ;
Wofsy, David ;
Eitner, Frank ;
Appel, Gerald B. ;
Contreras, Gabriel ;
Lisk, Laura ;
Solomons, Neil .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (20) :1886-1895
[10]   Foreword [J].
Eckardt, Kai-Uwe ;
Kasiske, Bertram L. .
KIDNEY INTERNATIONAL SUPPLEMENTS, 2012, 2 (01) :7-7